fda compounding semaglutide news today 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots What Patients Need to Know

Unlock Your Wellness Journey with GLP1/GIP Injections Embark on a transformative health journey with GLP1/ GIP injections, designed to revitalize your wellbeing

In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)

This is much of what I do now: working with people after GLP-1 use to put the missing half back in

For practitioners prescribing, patients receiving, and people choosing to purchase these medications privately, it's important to understand the risks of rapid weight regain if treatment ceases - and the value of wraparound behavioural support.' The researchers note several limitations